Outlook Therapeutics sets $485 LYTENAVA vial cost

Outlook Therapeutics, Inc. (OTLK) announced that it has established the wholesale acquisition cost for its product LYTENAVA™ in the United States at $485 per vial as of September 16, 2026.

Available on EDGAR 09/18/2026 - 04:31 PM EDT Accepted by SEC EDGAR 09/18/2026 - 04:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Outlook Therapeutics, Inc. (OTLK) announced that it has established the wholesale acquisition cost for its product LYTENAVA™ in the United States at $485 per vial as of September 16, 2026. This disclosure sets an initial list price reference for LYTENAVA in the U.S. market.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Wholesale acquisition cost per vial of LYTENAVA: $485 per vial

1 metrics

Wholesale acquisition cost per vial of LYTENAVA $485 per vial Established in the United States as of September 16, 2026

Key Terms

wholesale acquisition cost, Emerging growth company, Exchange Act

3 terms

wholesale acquisition cost financial

"established the wholesale acquisition cost for LYTENAVA™ in the United States"

Wholesale acquisition cost (WAC) is the manufacturer’s published price for a drug sold to wholesalers before discounts, rebates or other price concessions; think of it as the sticker price a maker sets for bulk buyers. Investors track WAC because it affects a company’s reported revenue potential, pricing power and profit margins, and because deviations between WAC and the actual net price can signal competitive pressure, reimbursement changes, or hidden costs.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Exchange Act regulatory

"pursuant to Rule 14a-12 under the Exchange Act"

A federal law that sets rules for trading securities on public exchanges, requiring companies and market participants to register, disclose regular financial information, and follow standards that promote honest, orderly markets. For investors, it matters because it creates transparency and legal protections—like stopping insider trading and ensuring timely company disclosures—so you can evaluate risks and rely on consistent rules much as players rely on a referee to keep a game fair.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What price did OTLK set for LYTENAVA in the United States?

Outlook Therapeutics set the wholesale acquisition cost for LYTENAVA™ in the United States at $485 per vial as of September 16, 2026.

When did OTLK establish the wholesale acquisition cost for LYTENAVA?

Outlook Therapeutics established the wholesale acquisition cost for LYTENAVA™ in the United States on September 16, 2026.

Does Outlook Therapeutics specify if $485 per vial is a wholesale acquisition cost or a different price type?

Outlook Therapeutics specifies that $485 per vial is the wholesale acquisition cost for LYTENAVA™ in the United States.

Where will LYTENAVA priced at $485 per vial be sold according to OTLK?

The company states that the $485 per vial wholesale acquisition cost applies to LYTENAVA™ in the United States.

What is the trading symbol and exchange for Outlook Therapeutics common stock?

Outlook Therapeutics’ common stock trades under the symbol OTLK on The Nasdaq Stock Market LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001649989 0001649989 2026-09-16 2026-09-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported): September 16, 2026

Outlook Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-37759	38-3982704
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

111 S. Wood Avenue, Unit #100 Iselin, New Jersey	08830
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (609) 619-3990

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock		OTLK		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events.

On September 16, 2026, Outlook Therapeutics, Inc. established the wholesale acquisition cost for LYTENAVA™ in the United States of $485 per vial.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Outlook Therapeutics, Inc.
Date: September 18, 2026		By:	/s/ Kevin Lundquist
			Kevin Lundquist
			Chief Financial Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.0 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.9 KB